Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:pharmaceutical_pricing_controversy
|
| gptkbp:beganIn |
2016
|
| gptkbp:concerns |
price increases
|
| gptkbp:involves |
gptkb:Mylan
gptkb:EpiPen |
| gptkbp:ledTo |
calls for regulatory reform
Mylan launching a generic EpiPen increased scrutiny of drug pricing |
| gptkbp:location |
gptkb:United_States
|
| gptkbp:mediaCoverage |
gptkb:CNN
gptkb:NPR gptkb:The_New_York_Times gptkb:The_Washington_Post |
| gptkbp:relatedTo |
gptkb:Heather_Bresch
pharmaceutical industry drug pricing in the United States |
| gptkbp:resultedIn |
investigations
public outcry congressional hearings generic alternatives |
| gptkbp:bfsParent |
gptkb:Heather_Manchin_Bresch
|
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
EpiPen price controversy
|